Which has higher valuation & earnings, SGP or TMDX?

TransMedics Group has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A TransMedics Group $605.49M 4.06 $190.29M $4.40 16.17

Does the media favor SGP or TMDX?

In the previous week, Spyglass Pharma had 1 more articles in the media than TransMedics Group. MarketBeat recorded 6 mentions for Spyglass Pharma and 5 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Spyglass Pharma's score of -0.04 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, LMAT or SGP?

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.71 $57.73M $2.71 35.10 Spyglass Pharma N/A N/A N/A N/A N/A

Does the media prefer LMAT or SGP?

In the previous week, Spyglass Pharma had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Spyglass Pharma and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.10 beat Spyglass Pharma's score of -0.04 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, AXGN or SGP?

Spyglass Pharma has lower revenue, but higher earnings than AxoGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.79 -$15.70M -$0.64 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Does the media favor AXGN or SGP?

In the previous week, Spyglass Pharma had 3 more articles in the media than AxoGen. MarketBeat recorded 6 mentions for Spyglass Pharma and 3 mentions for AxoGen. AxoGen's average media sentiment score of 0.26 beat Spyglass Pharma's score of -0.04 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ESTA or SGP?

Spyglass Pharma has lower revenue, but higher earnings than Establishment Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 10.43 -$51.06M -$1.49 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Which has stronger valuation and earnings, NVCR or SGP?

Spyglass Pharma has lower revenue, but higher earnings than NovoCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.98 -$136.23M -$1.53 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Does the media favor NVCR or SGP?

In the previous week, NovoCure had 9 more articles in the media than Spyglass Pharma. MarketBeat recorded 15 mentions for NovoCure and 6 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of -0.04 beat NovoCure's score of -0.12 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spyglass Pharma (SGP) Competitors

$18.74 -0.04 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$18.80 +0.07 (+0.35%)

As of 04:04 PM Eastern

Compare

SGP vs. TMDX, LMAT, AXGN, ESTA, and NVCR

Should you buy Spyglass Pharma stock or one of its competitors? MarketBeat compares Spyglass Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyglass Pharma include TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), Establishment Labs (ESTA), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Spyglass Pharma compare to TransMedics Group?

Spyglass Pharma (NASDAQ:SGP) and TransMedics Group (NASDAQ:TMDX) are both medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 140.13%. TransMedics Group has a consensus target price of $134.00, indicating a potential upside of 88.36%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Spyglass Pharma is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46

TransMedics Group has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
TransMedics Group	$605.49M	4.06	$190.29M	$4.40	16.17

TransMedics Group has a net margin of 27.04% compared to Spyglass Pharma's net margin of 0.00%. TransMedics Group's return on equity of 22.38% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
TransMedics Group	27.04%	22.38%	8.46%

In the previous week, Spyglass Pharma had 1 more articles in the media than TransMedics Group. MarketBeat recorded 6 mentions for Spyglass Pharma and 5 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.25 beat Spyglass Pharma's score of -0.04 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TransMedics Group beats Spyglass Pharma on 8 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LeMaitre Vascular has a net margin of 24.35% compared to Spyglass Pharma's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Spyglass Pharma	N/A	N/A	N/A

LeMaitre Vascular currently has a consensus price target of $112.60, suggesting a potential upside of 18.39%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 140.13%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.71	$57.73M	$2.71	35.10
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 3 more articles in the media than LeMaitre Vascular. MarketBeat recorded 6 mentions for Spyglass Pharma and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 0.10 beat Spyglass Pharma's score of -0.04 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LeMaitre Vascular beats Spyglass Pharma on 8 of the 12 factors compared between the two stocks.

How does Spyglass Pharma compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Spyglass Pharma has lower revenue, but higher earnings than AxoGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.79	-$15.70M	-$0.64	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 12.16%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 140.13%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Spyglass Pharma has a net margin of 0.00% compared to AxoGen's net margin of -13.21%. Spyglass Pharma's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 3 more articles in the media than AxoGen. MarketBeat recorded 6 mentions for Spyglass Pharma and 3 mentions for AxoGen. AxoGen's average media sentiment score of 0.26 beat Spyglass Pharma's score of -0.04 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Spyglass Pharma beats AxoGen on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Spyglass Pharma has lower revenue, but higher earnings than Establishment Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	10.43	-$51.06M	-$1.49	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Spyglass Pharma has a net margin of 0.00% compared to Establishment Labs' net margin of -19.05%. Spyglass Pharma's return on equity of 0.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 6 more articles in the media than Establishment Labs. MarketBeat recorded 6 mentions for Spyglass Pharma and 0 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.00 beat Spyglass Pharma's score of -0.04 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Establishment Labs	Neutral
Spyglass Pharma	Neutral

Establishment Labs currently has a consensus price target of $87.14, suggesting a potential upside of 16.44%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 140.13%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Spyglass Pharma beats Establishment Labs on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to NovoCure?

NovoCure (NASDAQ:NVCR) and Spyglass Pharma (NASDAQ:SGP) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Spyglass Pharma has lower revenue, but higher earnings than NovoCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.98	-$136.23M	-$1.53	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Spyglass Pharma has a net margin of 0.00% compared to NovoCure's net margin of -25.66%. Spyglass Pharma's return on equity of 0.00% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Spyglass Pharma	N/A	N/A	N/A

NovoCure presently has a consensus target price of $27.29, suggesting a potential upside of 61.93%. Spyglass Pharma has a consensus target price of $45.00, suggesting a potential upside of 140.13%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, NovoCure had 9 more articles in the media than Spyglass Pharma. MarketBeat recorded 15 mentions for NovoCure and 6 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of -0.04 beat NovoCure's score of -0.12 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Spyglass Pharma beats NovoCure on 7 of the 11 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$626.53M	$2.58B	$4.27B	$11.99B
Dividend Yield	N/A	N/A	9.68%	5.57%
P/E Ratio	N/A	0.63	18.25	21.95
Price / Sales	N/A	338.49	163.31	108.00
Price / Cash	N/A	7.68	46.51	37.25
Price / Book	N/A	5.53	30.05	6.78
Net Income	N/A	$7.39M	$118.48M	$337.51M
7 Day Performance	2.29%	-0.81%	-3.24%	-2.72%
1 Month Performance	-19.95%	0.15%	0.54%	1.87%
1 Year Performance	N/A	17.15%	12.35%	26.61%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	N/A	$18.74 -0.2%	$45.00 +140.1%	N/A	$626.53M	N/A	N/A	65
TMDX TransMedics Group	4.5133 of 5 stars	$69.01 +2.7%	$134.00 +94.2%	-50.1%	$2.33B	$635.89M	15.07	210
LMAT LeMaitre Vascular	4.5971 of 5 stars	$91.19 -3.7%	$112.60 +23.5%	+12.3%	$2.16B	$249.60M	33.40	490
AXGN AxoGen	2.4182 of 5 stars	$39.66 +0.5%	$46.50 +17.2%	+291.9%	$2.10B	$238.11M	N/A	450	Positive News Analyst Downgrade Gap Down
ESTA Establishment Labs	2.3972 of 5 stars	$72.23 +2.2%	$87.14 +20.6%	+95.6%	$2.00B	$229.58M	N/A	1,004	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, LMAT, AXGN, ESTA, and NVCR

How does Spyglass Pharma compare to TransMedics Group?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Summary

How does Spyglass Pharma compare to AxoGen?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Summary

How does Spyglass Pharma compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, LMAT, AXGN, ESTA, and NVCR

How does Spyglass Pharma compare to TransMedics Group?

Do insiders & institutionals believe in SGP or TMDX?

Do analysts recommend SGP or TMDX?

Which has higher valuation & earnings, SGP or TMDX?

Is SGP or TMDX more profitable?

Does the media favor SGP or TMDX?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Do insiders and institutionals hold more shares of LMAT or SGP?

Is LMAT or SGP more profitable?

Do analysts prefer LMAT or SGP?

Which has higher valuation & earnings, LMAT or SGP?

Does the media prefer LMAT or SGP?

Summary

How does Spyglass Pharma compare to AxoGen?

Which has better earnings and valuation, AXGN or SGP?

Do analysts recommend AXGN or SGP?

Is AXGN or SGP more profitable?

Does the media favor AXGN or SGP?

Do institutionals & insiders believe in AXGN or SGP?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Do institutionals and insiders have more ownership in ESTA or SGP?

Which has preferable earnings and valuation, ESTA or SGP?

Is ESTA or SGP more profitable?

Does the media favor ESTA or SGP?

Do analysts recommend ESTA or SGP?

Summary

How does Spyglass Pharma compare to NovoCure?

Which has stronger valuation and earnings, NVCR or SGP?

Is NVCR or SGP more profitable?

Do analysts recommend NVCR or SGP?

Does the media favor NVCR or SGP?

Do institutionals & insiders have more ownership in NVCR or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools